Subscribe
shutterstock_1066944104_siradawichitaphornkun
Sirada Wichitaphornkun / Shutterstock.com
21 August 2019AmericasSarah Morgan

Bayer to sell off animal health business for $7.6bn

Bayer has agreed to sell its animal health business to US-based Elanco Animal Health for $7.6 billion, as part of its strategic plan to focus on its core life sciences businesses.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Bayer buys BlueRock to build cell therapy expertise
9 August 2019   Bayer is set to acquire the rest of BlueRock Therapeutics, in a deal that values the Massachusetts-based cell therapy company at $1 billion.
Americas
BASF and Royal DSM embroiled in animal feed patent suits
16 April 2020   Bulgaria-based Huvepharma has accused chemicals company BASF and Dutch life sciences Koninklijke DSM, known as Royal DSM, of infringing its feed additive.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Bayer buys BlueRock to build cell therapy expertise
9 August 2019   Bayer is set to acquire the rest of BlueRock Therapeutics, in a deal that values the Massachusetts-based cell therapy company at $1 billion.
Americas
BASF and Royal DSM embroiled in animal feed patent suits
16 April 2020   Bulgaria-based Huvepharma has accused chemicals company BASF and Dutch life sciences Koninklijke DSM, known as Royal DSM, of infringing its feed additive.

More on this story

Americas
Bayer buys BlueRock to build cell therapy expertise
9 August 2019   Bayer is set to acquire the rest of BlueRock Therapeutics, in a deal that values the Massachusetts-based cell therapy company at $1 billion.
Americas
BASF and Royal DSM embroiled in animal feed patent suits
16 April 2020   Bulgaria-based Huvepharma has accused chemicals company BASF and Dutch life sciences Koninklijke DSM, known as Royal DSM, of infringing its feed additive.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent